Dow Pharmaceutical Sciences

Dow Pharmaceutical Services can design, develop and optimize your topical formulation, utilizing skin penetration studies from our Skin Biology Laboratory. We provide analytical method development and validation, stability testing, clinical materials manufacturing, and labeling and distribution of your clinical trial materials.

Contact Details: 1330A Redwood Way Petaluma CA 94954 United States of America Tel: 707-763-2600 Fax: 707-763-0145 Email: WWW: www.dowpharm.com/

Loading...

Recent Publications by Dow Pharmaceutical Sciences:
The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel. Fixed combination products of clindamycin 1% (as 1.2% clindamycin...	29th July, 2009	Dow Pharmaceutical Sciences, Inc., Petaluma, CA 94954-7121, USA.	J Drugs Dermatol. 2009 Jul;8(7):634-8.
Development of a gel permeation chromatographic assay to achieve mass balance in cellulose acetate phthalate stability studies. Cellulose acetate phthalate (CAP, cellulose acetate...	1st May, 2009	Dow Pharmaceutical Sciences, Inc., 1330 Redwood Way, Petaluma, CA 94954,	J Pharm Biomed Anal. 2009 Feb 20;49(2):240-6. Epub 2008 Nov 5. DOI Direct Link
A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3). Rosacea is a common chronic dermatosis that often is characterized by the...	6th June, 2006	Dow Pharmaceutical Sciences, Petaluma, California, USA.	Cutis. 2006 Apr;77(4 Suppl):18-26.
A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential. Rosacea is a common, recurrent, inflammatory dermatologic disorder...	6th June, 2006	Solano Clinical Research, Dow Pharmaceutical Sciences, Petaluma,	Cutis. 2006 Apr;77(4 Suppl):12-7.

Press Releases on Dow Pharmaceutical Sciences:
Valeant Buys-Out Rights to All Current and Future Income and Milestone Obligations From Former Dow Stockholders	29th September, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that, for a one-time payment of $115 million, it has agreed to buy-out income
Valeant Pharmaceuticals Reports First Quarter Financial Results	5th May, 2009	Valeant Pharmaceuticals International	- Revenue up 17%, 36% at constant exchange rates - GAAP EPS $0.37, adjusted Cash EPS $0.46 - Cash Flow from operations $51 million - Increased guidance for 2009, Cash EPS to $1.70 - 1.90 ALISO
'Topical Dermatological Product Development in the USA' Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA	9th April, 2009		PETALUMA, California, April 9 /PRNewswire/ -- Dow Pharmaceutical Sciences, Inc. today announced that it will hold a 1-day workshop on "Topical Dermatological Product Development in the USA"
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International	19th March, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar Chaudhuri to the position of President, Valeant
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results	24th February, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced fourth quarter and full year financial results for 2008. "With

BioNews Results for Dow Pharmaceutical Sciences:
Human Genome rallies, GTX craters	MarketWatch:  Nov 2 2009 5:46PM Matching: dow pharmaceutical sciences
Human Genome, Vertex, Amylin in play	MarketWatch:  Nov 2 2009 3:54PM Matching: dow pharmaceutical sciences
Biotech Stocks: Human Genome, Vertex, Amylin in play	MarketWatch:  Nov 2 2009 3:48PM Matching: dow pharmaceutical sciences
Proteome Sciences: Takeda Pharma Co Sign	Hemscott:  Oct 28 2009 7:34AM Matching: dow pharmaceutical sciences
Strategies for Supply-Chain Optimization	Pharmaceutical Technology:  Oct 7 2009 11:39PM Matching: dow pharmaceutical sciences
Promote your company here: BioNewsCast - Press Release Distribution	→View more Dow Pharmaceutical Sciences news.

Dow Pharmaceutical Sciences Clinical Trials:
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Dow Pharmaceutical Sciences Patents:
US Patent No.	Title
7368122	Skin cream
6387383	Topical low-viscosity gel composition
6468989	Gel compositions containing metronidazole
6517847	Topical gel delivery system
6589922	Skin cleanser comprising a steareth, poloxamer, and a glyceryl monoester
→View more Dow Pharmaceutical Sciences patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 217 times since April 2007, the link to the organisation's website has been followed 39 times

Search for more companies in Petaluma

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Dow Pharmaceutical Sciences